摘要
目的观察厄贝沙坦逆转原发性高血压左心室肥厚的疗效及安全性。方法根据入选标准纳入原发性高血压伴左心室肥厚患者90例，随机分为治疗组45例，对照组45例。治疗组给予厄贝沙坦片，每次150—300mg，1次／d。对照组给予卡托普利片，每次25～50mg，3次／d，观察6个月。观察治疗前后血压、左心室肥厚超声心动图指标变化，并检测血、尿、便常规、肝肾功能等指标，记录不良反应。结果2组血压均降低，治疗前后差异显著（P〈0．01），2组相比差异无显著意义（P〉0．05）；2组原发性高血压左心室肥厚均逆转，治疗前后差异显著（P〈0．05），2组相比差异无显著意义（P〉0．05）。在整个观察期间，药物不良反应发生率为：治疗组2．2％，对照组15．5％，2组差异显著（P〈0．01）。结论厄贝沙坦与卡托普利均能有效地降低血压，同时逆转左心室肥厚，而厄贝沙坦不良反应发生较少而轻微，耐受性好。
Objective To observe the therapeutic effects and security of lrbesartan on reversing left ventricular hypertrophy in patients with essential hypertension. Methods 90 patients with essential hypertension concomitant with left ventricular hypertrophy were randomly divided into two groups：therapeutic group （45 cases） and control group （45 cases）. The therapeutic group was treated with lrbesartan （150 -300 mg/d,qd） and the control group was treated with captopril （25 -50 mg,tid） for 6 months. The blood pressure （Bp） , echocardiographic changes, routine blood, urine and excrement, the function of liver and kidney were observed before and after treatment. Results The Bp of two groups were all decreased significantly after treatment （P 〈 0.01 ） , but there were no significant differences between two groups （P 〉 0.05 ）. The left ventricular hypertrophy was all significantly reversed after treatment （ P 〈 0.05） ,but there were no significant differences between two groups （P 〉 0.05 ）. The incidence of ad- verse reaction of the therapeutic and control group were 2.2% and 15.5% respectively. Conclusion Irbesartan and captopril can all decrease Bp and reverse left ventricular hypertrophy,but Irbesartan has little adverse effect which is easy to be tolerant.
出处
《河南职工医学院学报》
2009年第5期460-462,共3页
Journal of Henan Medical College For Staff and Workers
关键词
厄贝沙坦
卡托普利
左心室肥厚
原发性高血压
lrbesartan
captopril
left ventricular hypertrophy
essential hypertension
